Navigation Links
Helix BioPharma Corp. Announces Fiscal 2009 Results
Date:10/29/2009

AURORA, Ontario, Oct. 29 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: HBP / OTCQX: HXBPF) today announced financial results for the year ended July 31, 2009.

During the 2009 fiscal year, the Company continued to make progress with its development initiatives for its lead drug candidates, L-DOS47 and Topical Interferon Alpha-2b. The following are selected highlights during the 2009 fiscal year and subsequent to year-end.

FISCAL 2009 HIGHLIGHTS

DOS47/L-DOS47

  • A pre-IND meeting with the U.S. Food and Drug Administration ("FDA") was held for L-DOS47 in which the FDA generally agreed with Helix's proposed remaining non-clinical pharmacology and toxicology studies as well as its remaining GMP manufacturing program initiatives prior to IND filing.
  • Helix announced plans to conduct a Phase I/II clinical study of non-small cell lung cancer ("NSCLC") patients in Poland. Helix has been finalizing these plans with key opinion leader clinicians and contract research organizations in Poland. The study is expected to run concurrently with the U.S. Phase I trial in refractory solid tumor patients. The timing of both studies will be contingent on the timing of regulatory approvals of the trials as well as obtaining additional capital.

Topical Interferon Alpha-2b

  • A pre-IND meeting with the FDA was held in which the FDA confirmed the acceptability of a Phase II/III, randomized, vehicle-controlled clinical trial as the next step in the compound's clinical development plan for patients with cervical dysplasia. The FDA also confirmed Helix's expectation that an additional well-controlled, Phase III confirmatory clinical trial will be required to establish efficacy and safety of the product for marketing authorization purposes. Helix intends to continue to make preparations to conduct a European Phase III trial for this purpose.
  • The Phase II pharmacokinetic
    '/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
2. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
3. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
4. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
6. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
7. Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
8. PDL BioPharma Completes October 1 Special Dividend Payment
9. DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors
10. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
11. DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Echo ... medical device company focused on skin permeation, continuous ... Scott W. Hollander has been appointed ... Hollander has more than 20 years of experience ... industries, and most recently served as Vice President, ...
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... decision support to healthcare providers for behavioral health ... has secured $30 million in equity financing from ... C. Drosos , President and Chief Executive Officer. ... adoption and development of Assurex Health,s GeneSight ...
(Date:12/24/2014)... RALEIGH, N.C. , Dec. 23, 2014  Endo ... ENDP ) (TSX: ENL), and BioDelivery Sciences ... that they have submitted a New Drug Application (NDA) ... and Drug Administration (FDA).  Buprenorphine HCl Buccal Film is ... to require daily, around-the-clock, long-term opioid treatment and for ...
Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... 4, 2011 Novo Nordisk announced today the ... application (app) to assist in the diagnosis of ... Kessler, MD, Professor of Medicine and Pathology and ... Lombardi Comprehensive Cancer Center. Coags Uncomplicated features a ...
... 4, 2011 /PRNewswire-Asia-FirstCall/ – Lotus Pharmaceuticals, Inc. (OTC Bulletin ... a fast-growing, profitable developer, manufacturer and seller of medicine ... today announced that it will add two additional stories ... which is currently under construction and is scheduled to ...
Cached Medicine Technology:Novo Nordisk Creates First Mobile Application to Help Doctors Diagnose Bleeding Disorders 2Lotus Pharmaceuticals to Expand Construction of Beijing Facility 2Lotus Pharmaceuticals to Expand Construction of Beijing Facility 3
(Date:12/24/2014)... December 24, 2014 For nearly 20 ... housewarmings, new babies, graces, and all of life's rites ... and author, Nancy Tupper Ling, in Toasts: The ... Viva Editions. , Organized by category and containing ... won't appear anywhere else, this timely tome contains sayings ...
(Date:12/24/2014)... 2014 As 2014 draws to a ... before investing time and money into a new or ... that specializes in tankless and eco-friendly products or service. ... water heater in 2015 to research “green” and environmentally ... Greenstar Home Services specializes in eco-friendly and environmentally ...
(Date:12/24/2014)... Kathleen Doheny HealthDay Reporter ... steady diet of fast food might hurt your child in ... ate fast food in fifth grade lagged behind by eighth ... more than 8,500 U.S. students. "The largest effects were ... food," said study leader Kelly Purtell, assistant professor of human ...
(Date:12/24/2014)... News) -- Long-term fear of terrorists may damage your heart ... study from Israel suggests. , , Conducted by researchers from ... In Israel, the threat of war and terrorism has been ... "We wanted to test whether fear of terrorism can predict ... study author Hermona Soreq, a professor of molecular neuroscience, said ...
(Date:12/22/2014)... B. E. Smith, the only full-service leadership solutions ... to lead a national chief compliance officer search ... Calif. The top executive search firm in ... more than 900 healthcare executives into organizations. , ... Seal-approved, full-service acute-care hospital serving San Diego County’s coastal ...
Breaking Medicine News(10 mins):Health News:Greenstar Home Services Offers Tankless Water Heater Advice to Local Homeowners 2Health News:Can Fast Food Hinder Learning in Kids? 2Health News:Terrorism Fears May Shorten Your Life, Study Finds 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 3
... (HealthDay News) -- New guidelines on treating so-called "latent" tuberculosis ... the course of the therapy from about 9 months to ... and Prevention. The new guidelines for public health officials ... opinion and the results of three clinical trials -- are ...
... Los Angeles, CA (DECEMBER 8, 2011) Young football players may ... study released in Journal of Child Neurology (JCN), ... and Dr. Meredith R. Golomb looked at various case studies ... and found some potential causes for strokes in young football ...
... Exercise is good medicine, and the number of American adults ... from 31 percent in 1989 to 25 percent in 2008, ... to achieve because certain subgroups of people are highly unlikely ... report from the U.S. Centers for Disease Control and Prevention. ...
... week by the National Institutes of Health has ... cancer should be closely monitored, permitting treatment to ... monitoring strategiessuch as active surveillancehave not been uniformly ... to clear follow-up protocols. The panel recommended standardizing ...
... -- Some women who inherit the BRCA1 or BRCA2 breast ... with breast cancer nearly a decade earlier than those who ... Researchers examined the family trees of 128 breast or ... determine the origins of the patients, cancer genes. "No ...
... use bust-enhancing dietary supplements containing the mycoestrogen zearalenone (ZEN), ... could be increasing their risk of breast cancer. That ... paper published online ahead of print publication in the ... Journal of Clinical Practice . "No clinical trials ...
Cached Medicine News:Health News:CDC Issues New TB Treatment Guidelines 2Health News:More Americans Exercise, but Arthritis Can Get in the Way 2Health News:Panel endorses active monitoring and delay of treatment for low-risk prostate cancer 2Health News:Panel endorses active monitoring and delay of treatment for low-risk prostate cancer 3Health News:Family Tree May Affect Diagnosis Age in Some Breast Cancers 2Health News:Women advised to avoid ZEN bust-enhancing supplements because of possible cancer risk 2
Pneumatic micro sagittal saw, 30k cpm, available with various hose connector styles....
... power line from MicroAire. Our new ... electric instruments, offering the ultimate in ... has always wanted with the security ... Power Master reciprocating saw, Available with ...
... The 7600 Oscillating Saw offers ... osteotomies, thanks to its 14.4V ... cutting head may be rotated ... in any plane and will ...
... Brasseler USAs Large Bone Power System ... offers new technological advancements. The truly innovative ... power pack, which is comprised of the ... handpiece contains only mechanical components, which provides ...
Medicine Products: